Auckland, New Zealand
Auckland, New Zealand

Time filter

Source Type

Liden B.A.,Reynoldsburg Podiatry Center | May B.C.H.,Mesynthes
Advances in Skin and Wound Care | Year: 2013

The suitability of the ovine forestomach matrix (OFM) for the treatment of recalcitrant wounds was evaluated in 19 patients. At 12 weeks, 50% of wounds had closed, and the average reduction in surface area was 73.4%. Promising outcomes of this initial series support the clinical consideration of OFM. Copyright © 2013 Lippincott Williams & Wilkins.


McNatty K.P.,Victoria University of Wellington | Heath D.A.,Victoria University of Wellington | Hudson N.L.,Victoria University of Wellington | Reader K.L.,Agresearch Ltd. | And 3 more authors.
Reproduction | Year: 2010

In mammals with a low ovulation rate phenotype, ovarian follicular development is thought to be hierarchical with few, if any, antral follicles at similar stages of development. The hypothesis being tested herein was that if most follicles are in a functionally different state, then the application of exogenous hormones to increase ovulation rate will not overcome the hierarchical nature of follicular development. Using sheep as the experimental model, the functional states of all non-atretic antral follicles ≥2 mm diameter were assessed in individual ewes (N=10/group) during anoestrus with or without pregnant mare's serum gonadotrophin (PMSG) treatment, or after a standard superovulation regimen, or during the follicular phase of the oestrous cycle. The functional states of these follicles were assessed by measuring the FSH- or human chorionic gonadotrophin (hCG)-induced cAMP responses of granulosa cells in vitro. There were significant overall effects across the treatment groups on the responses of granulosa cells to either FSH or LH (both P<0.001). It was concluded that for anoestrous ewes with or without PMSG treatment, and ewes during the follicular phase, granulosa cell populations of many follicles (≥2 mm diameter) did not share a similar cAMP response to FSH (∼50% of follicles) or hCG (>90% of follicles) either on a per cell or total cell basis. After superovulation, ≤30 and 10% respectively of the granulosa cell populations shared similar responses to FSH and LH with regard to follicular diameter and cAMP output. Thus, exogenous hormone treatments used routinely for increasing oocyte yield do not effectively override the hierarchical pattern of ovarian follicular development during the follicular phase. © 2010 Society for Reproduction and Fertility.


Negron L.,Mesynthes | Lun S.,Mesynthes | May B.C.,Mesynthes
International Wound Journal | Year: 2014

Proteases play a critical role in the ordered remodelling of extracellular matrix (ECM) components during wound healing and tissue regeneration. However, the usually ordered proteolysis is compromised in chronic wounds due to over-expression and high concentrations of matrix metalloproteinase's (MMPs) and neutrophil elastase (NE). Ovine forestomach matrix (OFM) is a decellularised extracellular matrix-based biomaterial developed for tissue regeneration applications, including the treatment of chronic wounds, and is a heterogeneous mixture of ECM proteins and proteoglycans that retains the native structural and functional characteristics of tissue ECM. Given the diverse molecular species present in OFM, we hypothesised that OFM may contain components or fragments that inhibit MMP and NE activity. An extract of OFM was shown to be a potent inhibitor of a range of tissue MMPs (IC50s = 23 ± 5 to 115 ± 14 μg/ml) and NE (IC50 = 157 ± 37 μg/ml), and was more potent than extracts prepared from a known protease modulating wound dressing. The broad spectrum activity of OFM against different classes of MMPs (i.e. collagenases, gelatinases and stromelysins) may provide a clinical advantage by more effectively addressing the protease imbalance seen in chronic wounds. © 2012 Medicalhelplines.com Inc and John Wiley & Sons Ltd.


The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.


The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.


The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.


Patent
Mesynthes | Date: 2015-08-19

The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold.


Trademark
Mesynthes | Date: 2016-05-17

Surgical apparatus and instruments for medical, dental and veterinary use; medical, surgical and orthopaedic implants made of artificial materials; suture materials. Medical services; veterinary services; hygienic and beauty care for human beings or animals.


Trademark
Mesynthes | Date: 2012-10-16

Surgical apparatus and instruments for medical, dental and veterinary use; suture materials; non-living regenerative tissue substitute for use in wound care and soft tissue reconstruction.

Loading Mesynthes collaborators
Loading Mesynthes collaborators